US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
アメリカ
NASDAQ
Greenidge Generation Holdings Inc (GREEL) 銘柄情報

Greenidge Generation Holdings Inc (GREEL)

20.94

-0.06

(-0.29%)

終了 6月6日 5:00AM

20.94

0.00

(0.00%)

取引時間後: 8:59AM

Greenidge Generation Holdings Inc (GREEL) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

20.94

( -0.29% )

買値

14.66

売値

22.50

出来高

833

20.94 日の範囲 21.00

7.50 52 週間の範囲 22.055

前日終値

21.00

始値

21.00

時刻

最終取引時間

平均取引量 (3 か月)

3,695

財務取引量

US$ 17,460

VWAP

20.96

Form 8-K - Current report

Form 8-K - Current report

Form S-3 - Registration statement under Securities Act of 1933

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Form 8-K - Current report

Greenidge Generation Announces Expiration and Final Results of Exchange Offer for Senior Notes Due 2026

Greenidge Generation Holdings Inc. (Nasdaq: GREE) (“Greenidge” or the “Company”), a vertically integrated power generation company focused on...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.66	-3.05555555556	21.6	21.9615	19.75	4275	21.44824974	CS
4	1.48	7.60534429599	19.46	21.9615	18.89	3990	20.61457259	CS
12	-0.06	-0.285714285714	21	22	18.6718	3695	20.65309943	CS
26	4.49	27.2948328267	16.45	22.055	15.1	4917	19.53994756	CS
52	13.39	177.350993377	7.55	22.055	7.5	5828	14.0611421	CS
156	16.46	367.410714286	4.48	22.055	3.78	7060	9.86701906	CS
260	-4.06	-16.24	25	25.425	0.5501	10139	10.33322754	CS

GREEL - Frequently Asked Questions (FAQ)

What is the current Greenidge Generation Holdings Inc share price?

The current share price of Greenidge Generation Holdings Inc is US$ 20.94

What is the 1 year trading range for Greenidge Generation Holdings Inc share price?

Greenidge Generation Holdings Inc has traded in the range of US$ 7.50 to US$ 22.055 during the past year

US Market News

US Market News 4分前

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA BerobenatideJune 6, 2026 9:00 AM
Business Wire Results from multiple Phase 2b dose finding studies for berobenatide (PF’3944) highlight a potential first-in

Investor082

Investor082 4分前

They are all a bunch of BS artists! They have trapped many naive retail families over the years by providing false hope and expectations.

Investor082

Investor082 6分前

See you in 2028 then! LP is likely to abandon Eden before that at some point than secure a commercial certification in 2028.

Keep a ton of dry powder. Looking forward to you bragging about averaging down in the coming weeks and months, LOL! ;)

Investor082

Investor082 9分前

In that case, forget about 2026 and 2027. Likely 2028 as well. C lab and Eden won’t certified for commercial production until 2028 at the earliest. Its more likely they will abandon Eden than secure commercial certification even in 2028. Have fun with the endless dilution in pennies! ;)

WhiteOwl

WhiteOwl 10分前

Am I missing something or does that Video say everything is experimental or just theory? I was under the impression they had perfected a workable unit? Just saying.

THE OLD OWL 🦉🦉🦉

hardlesson

hardlesson 13分前

You're one of the hardest working guys on ihub. Banging out the charts on a Saturday morning. Thanks always, and have a good weekend. :)

Investor082

Investor082 13分前

LP will be back there again in a couple years still pleading for a change (pathway act) so she can submit regulatory application to FDA in 2030, LOL!

Meanwhile outstanding shares ballooned to 5B+, LOL! ;)

WhiteOwl

WhiteOwl 13分前

Am I missing something or does that Video say everything is experimental or just theory? I was under the impression they had perfected a workable unit? Just saying.

THE OLD OWL 🦉🦉🦉

glenn1919

glenn1919 17分前

BCDA......BMGL.......BGMS......ACCL......CMND.........CGTL...........https://stockcharts.com/sc3/ui/?s=CMND&p=w&yr=1&mn=3&dy=0&id=p96837884856

Investor082

Investor082 18分前

No excuses when LP disappoints on this, OK?

I will check in on this message whenever there is a decision, LOL! ;)

WhenLambo

WhenLambo 18分前

FIFA is already on public record marketing them, what could be bigger than that? They’ll continue to put VuMe out there next week

train21

train21 19分前

DRIVEN IS BACK
so I guess we going to see 5 cents again ? well are we ?

Investor082

Investor082 20分前

Don't let LP and her toxic financiers screw you year after year, LOL! ;)

Instead invest in well known AI and tech stocks run by solid management crew.

glenn1919

glenn1919 21分前

STAK......SPHL.....SMTK......SAOR.....SNBR.......SCAG.....SPPL..................................https://stockcharts.com/sc3/ui/?s=SCAG&p=w&yr=1&mn=3&dy=0&id=p96837884856

jackinthegreen

jackinthegreen 22分前

Exactly - another round of press and hype can drive the price up a bit, but without substantial new contracts and revenue outside the consumer electronics space, it will only be a temporary bump. We’ve been here before - buying on the rumor is great, but what we need is actual profitability.

train21

train21 22分前

BOTH CEOs BLOCKED ME ON X
I MUST HAVE HIT THE NAIL ON THE HEAD
ANY CEO THAT BLOCKS QUESTIONS OF THEIR DECISIONS IS HIDING SOMETHING BIG AND BAD ???

rodman

rodman 23分前

There appears to be some life left in UEEC based upon the buying and pps increase this week.

cottonmather

cottonmather 23分前

Drey Dossier. The WH Ballroom ain't what it used to be. 17 minutes https://youtu.be/VbJ4ilDvGyc?si=DispyZYqLVQNJyms

USAFpatriot

USAFpatriot 23分前

Annual meeting 8k.

https://investorshub.advfn.com/stock-market/NASDAQ/novocure-NVCR/stock-news/98686681/form-8-k-current-report

train21

train21 24分前

$GTVH YOU ALL NEED TO FILE COMPLAINTS ON THE $OTC WEB SITE AND THE $FINRA WEB SITE
I CAN NOT JUST BE THE ONLY ONE FILING COMPLAINTS HERE ? SOME OF YOU GUYS LOST THOUSANDS $$$$$
CASEY IS A SHARE SELLING SCAMMMER AND MEDIA POSTING LIAR ......... AND THATS ALL THIS STOCK IS

HGiLS

Absolutely — let’s build the full, structured deep-dive you asked for. Below is everything:

• All Eliquis ANDA filers
• Their litigation outcomes
• Each filer’s non-infringement arguments
• Why none succeeded
• Drugs where generics did win using alternative

peafunke

peafunke 26分前

You told ‘who’ so? The fifa concerts are this coming week.

HGiLS

Yes — Eliquis (apixaban) has exactly the kind of ANDA litigation you’re asking about: cases where a generic filer challenged the Orange Book patents and argued non-infringement because their own formulation or manufacturing approach did not fall within the scope of the listed patents.

Teddytropics

Teddytropics 29分前

I will leave it up to you to decide..

I ask myself.. why is this guy so obsessed with Jason Black..?

That he wants to 'to tell on Jason Black' to all..

Where Jason Black isn't involved here anymore except for the CNNA OTC page still listing him..

Greenidge Generation

Germany Federal Republic

Euronext MTS EGB Italy 1...

iNAV Xtrackers II US Tre...

FTAC Emerald Acquisition

New Energy Solar

Churchill Capital Corp IV

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。